
News|Articles|August 1, 2004
Etanercept/anakinra RA combination therapy has increased risk compared to etanercept monotherapy
Etanercept/anakinra combination therapy for the treatment of rheumatoid arthritis (RA) provides no added benefit and has an increased risk compared to etanercept alone, according to a study published in Arthritis & Rheumatism, the journal of the American College of Rheumatology (ACR).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
TrumpRx launches; some experts question its long-term value
3
PBM reform. It has finally happened
4
What exactly is managed care today?
5























